Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2018
Specialty Drug Pipeline Review Focuses on Competition, Cancer Drugs
April 24, 2018
Dr Robert Navarro Discusses Progress in Shift to Value-Based Care
April 24, 2018
Brian Litten Outlines How Medication Therapy Management Can Address Opioid Misuse
April 24, 2018
Who Decides What Value Looks Like in US Healthcare?
April 24, 2018
Dr Brandon Newman Discusses Payer, Academic Medical Center Collaboration
April 25, 2018
Dr Aimee Tharaldson Discusses Key Market Trends in Specialty Pharmacy
April 25, 2018
Migraines in the US Are More Than Just a Pain Problem
April 25, 2018
Market Access Teams Face New Challenges in Pharma
April 25, 2018
Currently Reading
Cardiologist Talks About Value of Monoclonal Antibody Evolocumab
April 26, 2018
Dr Tina Joseph Discusses Collaborative Practice Agreements Between Pharmacists, Physicians
April 26, 2018
Navigating the Rocky Waters to Value-Based Healthcare
April 26, 2018
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26, 2018
Dr Aimee Tharaldson on Recently Approved Specialty Drugs, Upcoming Approvals to Watch
May 05, 2018
Dr Calvin Knowlton Outlines Benefits Seen From Enhanced Medication Therapy Management
May 06, 2018
The Rise of Orphan Drugs for Rare Diseases
May 07, 2018
Dr Robert Navarro Foresees Unintended Consequences From Shift to Value-Based Care
May 12, 2018
Dr Kimberly Lenz: Identifying Patients Most at Risk For Substance Abuse
May 13, 2018
Brian Litten Outlines Challenges With Adopting Medication Therapy Management Services
May 17, 2018
Dr Tina Joseph Outlines Pharmacists' Role in Managing Chronic Diseases, Value-Based Care Models
May 19, 2018
Dr Calvin Knowlton on Innovative Practices in Enhanced Medication Therapy Management
May 20, 2018
Dr Ashley Pappas Discusses Collaboration Between Academic Centers and Payers
May 24, 2018
Dr Robert Navarro on Pharma Implementing Value, Best Practices for Value-Based Contracts
May 25, 2018
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27, 2018
Dr Kimberly Lenz on Implementing, Enforcing Appropriate Opioid Prescribing
June 04, 2018

Cardiologist Talks About Value of Monoclonal Antibody Evolocumab

Allison Inserro
During a Science and Innovation Product Theater, sponsored by Amgen, Seth J. Baum, MD, FAAC, FACPM, FAHA, FNLA, FASPC, president of the American Society for Preventive Cardiology, explained the significance of evolocumab's expanded indication, which makes it no longer mandatory for patients to try statins first.
A leading cardiologist and supporter of a monoclonal antibody that works to slash “bad” cholesterol spoke Wednesday at the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting held April 23-26, in Boston, Massachusetts, to discuss evolocumab's value and how it is being underutilized despite a December labeling change by the FDA.

Seth J. Baum, MD, FAAC, FACPM, FAHA, FNLA, FASPC, president of the American Society for Preventive Cardiology, talked about evolocumab (Repatha) at the Science and Innovation Product Theater, sponsored by Amgen, maker of Repatha. In “Understanding the Value of Repatha,” Baum made sure the audience understood the significance of the expanded indication.

Evolocumab, first approved in 2015, is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and blocks the PCSK9 enzyme, preventing its ability to stymie the liver from filtering low-density lipoprotein (LDL) cholesterol out of the blood. PCSK9 inhibitors can reduce LDL cholesterol by up to 60%.

The approval was first limited to high-risk patients and those with genetic conditions that cause high cholesterol. With the expanded indication, “it is no longer mandatory to try statins,” said Baum. Statins are still the first line of treatment, but payers should stop emphasizing how many trials of statins a patient must go through before being permitted to try evolocumab, he said. Instead, patients should be treated according to their risk.

Baum said evolocumab is indicated for prevention of cardiovascular events in adults with established cardiovascular disease to reduce the risk of heart attack, stroke and coronary revascularization. The secondary indication is for primary hyperlipidemia where the drug, as an adjunct to diet alone or in combination with other lipid-lowering agents like statins, can treat adults with primary hyperlipidemia to reduce LDL cholesterol.

Current guidelines advise lowering LDL cholesterol to below a target of ≤70 mg/dL. But despite treatments with maximum statin therapy, 80% of adults with established cardiovascular disease are not achieving that goal, he said.

In addition, about 7.6% of patients with cardiovascular disease and LDL choleseterol levels greater than 70 mg/dL treated with statins experience a recurring event annually. Of those, 3.2% have a revascularization, 2.3% have a heart attack and 2.1% have a stroke, Baum said.

Baum also reviewed results from the FOURIER trial, which were released late last year. The greatest effect was seen when the drug was started on patients who had had a qualifying cardiovascular event within the prior 2 years. In other words, treat early and aggressively, Baum said. 

Baum also referred to the valuation studies that have been done on evolocumab or other drugs by places like the Institute of Clinical and Economic Research or payers, who think the treatments should be priced less. In his view, the reports will depend on what criteria are being used at the outset (inputs) and in addition, real-word events will always have more data than clinical trials. Valuation reports that reflect only clinical trials may not reflect all factors, he said.

"Real-world data gives a much better sense of the value of the medication," Baum said.

Related Articles

Evolocumab Results Unveiled at Packed Session: Phase 3 Studies Show Significant Lowering of LDL Cholesterol
Cholesterol-Fighting Drug Evolocumab Also Reduces Cardiovascular Events, Study Finds
Adding Evolocumab to Standard ASCVD Treatment Exceeds Cost-Effectiveness Threshold
More FOURIER Results Highlight Evolocumab Outcomes Among Higher-Risk Patients
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up